Pharmacopeia acquires selective androgen receptor modulator program from Bristol-Myers.
Publication Date: 01-SEP-07
Publication Title: BIOTECH Patent News
Format: Online
Company: Bristol-Myers Squibb Co.

Read this article now
Try Goliath Business News - FREE!
You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News
Free for 7 Days!

Tell Me More   Terms and Conditions

Purchase this article for $4.95

Description

Pharmacopeia (Princeton, CA), an innovator in the discovery and development of novel small molecule therapeutics, announced that it has licensed from Bristol-Myers Squibb (New York, NY) a selective androgen receptor modulator (SARM) program, including a lead compound in Phase 1 clinical development and back-up compounds. PS178990 is a non-steroidal selective androgen receptor modulator, or SARM, which...



More articles from BIOTECH Patent News
University of Southern California obtains United States patent., September 01, 2007
Celtrix obtains United States patent., September 01, 2007
Monsanto obtains United States patent., September 01, 2007
ProChon obtains United States patent., September 01, 2007
Degussa obtains United States patent., September 01, 2007

Looking for additional articles?
Click here to search our database of over 3 million articles.